|Chemical and physical data|
|Molar mass||358.422 g·mol−1|
|3D model (JSmol)|
Olorinab (APD371) is a drug being developed by Arena Pharmaceuticals for the treatment of gastrointestinal pain associated with Crohn's disease and irritable bowel syndrome. It acts as a potent and selective cannabinoid CB2 receptor agonist and is claimed to be orally active and peripherally selective. Initial Phase IIa exploratory clinical trials have been successful, with Phase IIb trials projected to start in 2019.
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|